deltatrials
Completed PHASE2/PHASE3 NCT02589782

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis

Sponsor: Drugs for Neglected Diseases

Updated 12 times since 2017 Last updated: Apr 30, 2024 Started: Jan 31, 2017 Primary completion: Aug 5, 2022 Completion: Aug 5, 2022

Listed as NCT02589782, this PHASE2/PHASE3 trial focuses on Extensively Drug-Resistant Tuberculosis and Tuberculosis, Multidrug-Resistant and remains completed. Sponsored by Drugs for Neglected Diseases, it has been updated 12 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotRecruiting~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotRecruiting~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshotRecruiting~Aug 2019 – ~Nov 2020 · 15 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshotRecruiting~Jun 2021 – ~Jun 2023 · 24 months · monthly snapshotActive Not Recruiting~Jun 2023 – ~Jun 2024 · 12 months · monthly snapshotUnknown Status~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Status: Unknown StatusCompleted

  4. Jun 2023 — Jun 2024 [monthly]

    Unknown Status PHASE2_PHASE3

    Status: Active Not RecruitingUnknown Status

  5. Jun 2021 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

Show 7 earlier versions
  1. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2_PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  3. Aug 2019 — Nov 2020 [monthly]

    Recruiting PHASE2_PHASE3

  4. Jun 2018 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

  5. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  6. Feb 2017 — Apr 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet RecruitingRecruiting

  7. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Drugs for Neglected Diseases
  • Global Alliance for TB Drug Development
  • London School of Hygiene and Tropical Medicine
  • Medecins Sans Frontieres, Netherlands
  • Ministry of Health, Republic of Uzbekistan
  • Ministry of Public Health, Republic of Belarus
  • Rutgers, The State University of New Jersey
  • Swiss Tropical & Public Health Institute
  • THINK TB & HIV Investigative Network
  • University College, London
  • University of California, San Francisco
  • University of Liverpool
  • Wits Health Consortium (Pty) Ltd
  • World Health Organization
  • eResearch Technology, Inc.
Data source: Medecins Sans Frontieres, Netherlands

For direct contact, visit the study record on ClinicalTrials.gov .